Disease Focus: Cancer
2nd Generation Vaccine for the Treatment of Glioblastoma
Translational Candidate It is the peptide LEEKKYNYVVVTDHC conjugated to KLH and used as an anti-cancer vaccine. Area of Impact This is a better optimized, more robust vaccine that aspires to greatly improve glioblastoma patient survival over the current vaccine. Mechanism of Action The vaccine stimulates B cell and T cells. We have found this may […]
62nd Midwinter Conference of Immunologists
The American Society for Transplantation and Cellular Therapy (ASTCT)/The European Society for Blood and Marrow Transplantation (EBMT) 6th International Conference on Relapse after Transplant and Cellular Therapy
Phase 1 Study of Autologous E-SYNC T Cells in Adult Participants with EGFRvIII+ Glioblastoma
Therapeutic Candidate or Device Human T cells transduced with a lentiviral vector encoding anti-EGFRvIII synNotch-primed anti-EphA2/IL-13Rα2 chimeric antigen receptor. Indication Patients with MGMT unmethylated newly diagnosed GBM (Cohort 1), and patients for whom re-resection of recurrent GBM (Cohort 2). Therapeutic Mechanism In our proposed system, the first antigen EGFRvIII, which is expressed exclusively but heterogeneously […]
A Phase I/IIa Study to Evaluate the Efficacy of Toca 511/Toca FC with Standard of Care Therapy in Newly Diagnosed High Grade Glioma
Therapeutic Candidate or Device DB107 (Toca 511), a retroviral replicating vector expressing yeast cytosine deaminase, which converts an antifungal prodrug to an anticancer drug Indication Newly diagnosed high-grade glioma Therapeutic Mechanism Retroviral replicating vector DB107 (Toca 511) spreads through tumors and delivers yeast cytosine deaminase (CD), which converts the antifungal prodrug 5-fluorocytosine (5-FC) to the […]
A PHASE 1B STUDY EVALUATING THE SAFETY AND EFFICACY OF AN ALLOGENEIC CELL THERAPY IN SUBJECTS WITH CLEAR CELL RENAL CELL CARCINOMA (ccRCC)
Therapeutic Candidate or Device An allogeneic anti-CD70 CAR-T cell product will be evaluated for the treatment of advanced or metastatic clear cell renal cell carcinoma (ccRCC). Indication Advanced or metastatic clear cell renal cell carcinoma (ccRCC) Therapeutic Mechanism The product is an allogeneic TRAC/CD52-knockout CAR T cell therapy targeting CD70. In this clinical study, the […]
Phase I Study of Chimeric Antigen Receptor Engineered T Cells targeting CD33 for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Therapeutic Candidate or Device Immune T cells from a patient’s transplant donor engineered to express chimeric antigen receptors for targeted leukemia killing Indication Relapsed or refractory acute myeloid leukemia Therapeutic Mechanism Upon adoptive transfer, patient specific immune T cells that express chimeric antigen receptors will specifically recognize and directly kill leukemia cells expressing CD33. Unmet […]
Phase I Trial of Locoregionally Delivered Autologous B7-H3 CAR T Cells (B7-H3CART) in Adults with Recurrent Glioblastoma Multiforme
Therapeutic Candidate or Device Autologous T cells genetically engineered to express a Chimeric Antigen Receptor targeting B7-H3 (B7-H3CART) Indication Brain tumors in adults: Glioblastoma Multiforme (GBM) Therapeutic Mechanism Progenitor B7-H3CART cells will recognize GBM cancer cells expressing B7-H3, become activated, divide, and kill the cancer cells Unmet Medical Need Glioblastoma Multiforme (GBM) is the most […]
Stem-Derived IL13Ra2 Chimeric Antigen Receptor T cells for Patients with Melanoma and Advanced Solid Tumors
Therapeutic Candidate or Device Adult Stem-Like T cells engineered with chimeric antigen receptor (CAR) to target cancers expressing IL13Ra2, including melanoma. Indication Advanced cancers that express IL13Ra2, including melanoma. Therapeutic Mechanism When administered to a patient, the engineered T cells will circulate through the blood and tissues to nd, recognize and kill tumor cells that […]
Autologous ARTEMIS® T Cells to Treat Refractory/Relapsed Pediatric Liver Cancer
Therapeutic Candidate or Device ET140203 T cells: engineered T-cell therapy whereby autologous T cells are modified to specifically target and kill AFP+/ HLA-A2+ cancer cells. Indication Pediatric subjects aged ≥ 1 year to ≤ 21 years who are AFP-positive/HLA-A2-positive and have relapsed/refractory (r/r) HB, HCN-NOS, or HCC. Therapeutic Mechanism ET140203 T-cell therapy is designed to […]